Mefloquine-induced enhancement of sIPSCs was significantly attenuated in the presence of the anticholinesterase agent physostigmine, or blockers of non-α7 nicotinic acetylcholine receptors. Taken together, these data suggest that mefloquine enhances GABA release through its inhibition of cholinesterase. This allows accumulation of endogenously released acetylcholine which activates neuronal nicotinic receptors on GABAergic nerve terminals. The resultant increase of Ca 2+ entry into these terminals enhances vesicular release of GABA. This action may contribute to the neurobehavioral effects of mefloquine.
Introduction
Mefloquine is a widely used antimalarial drug because of its effectiveness against chloroquine-resistant plasmodia. It is well known that this benefit of mefloquine is offset by many adverse side effects on both the central and peripheral nervous systems (Fuller et al., 2002; Wooltorton, 2002; Falchook et al., 2003; Kukoyi and Carney., 2003; Meier et al., 2004) . The most notable adverse effects are neuropsychiatric disturbances of anxiety, confusion, dizziness, and dysphoria. The cellular basis of these effects is not understood.
Synaptic transmission is of great importance in the interplay between cells of the nervous system. Recently, several studies reported that mefloquine potently altered synaptic transmission in rodent central nervous system and peripheral synapses. Specifically, mefloquine robustly enhanced the frequency of spontaneous excitatory postsynaptic potentials in rat hippocampal slices (Cruikshank et al., 2004) . Likewise, mefloquine significantly increased the frequency as well as decay time, of miniature endplate potentials (mepps) at the mouse neuromuscular junction (McArdle et al., 2005 (McArdle et al., , 2006 . Since the intracellular Ca 2+ buffer BAPTA-AM prevented the effect of mefloquine on mepp frequency, it was suggested that mefloquine alters storage of Ca 2+ within motor nerve endings. On the other hand, the prolongation of mepp decay time appeared to depend on the anticholinesterase action of mefloquine (Lim and Go, 1985) . The relevance of these findings to the neuropsychiatric effects of mefloquine remains unclear.
Central dopaminergic (DA) neurons regulating cognitive and motor processes are located in the ventral mesencephalon, including substantia nigra and ventral tegmental area. The substantia nigra pars compacta (SNc) possesses a dense area of DA neurons, receiving GABAergic inhibition primarily from neurons in substantia nigra pars reticulate, pallidum, striatum, and nucleus accumbens (Giustizieri et al., 2005) . The GABAergic inputs control the excitability of DA neurons (Tepper et al., 1998) . The fact that SNc DA neurons can be isolated along with attached GABAergic terminal boutons (Akaike and Moorhouse, 2003; Ye et al., 2004) , presents an opportunity to evaluate the effect of mefloquine on spontaneous GABA release in some detail.
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Materials and Methods
Slice preparation and mechanical dissociation. The care and use of animals, and the experimental protocol, were approved by the Institutional Animal Care and Use Committee of the University of Medicine and Dentistry of New Jersey. The midbrain slices were prepared as described previously (Ye et al., 2004; Zhou et al., 2006) . In brief, rats, aged 6-17 postnatal days, were decapitated, and the brain was quickly excised and coronally sliced (300 µm) with a VF-100
Slicer (Precisionary Instruments, Greenville, NC). This was done in ice-cold artificial cerebrospinal fluid (ACSF) saturated with 95% O 2 / 5% CO 2 (carbogen) containing: 126 mM NaCl, 1.6 mM KCl, 1.25 mM NaH 2 PO 4 , 1.5 mM MgCl 2 , 2 mM CaCl 2 , 25 mM NaHCO 3 , and 10 mM glucose. Midbrain slices were then kept in carbogen-saturated ACSF at room temperature (22-24 °C) for at least 1 hr before use.
Neurons, with functional terminals, were obtained by mechanical dissociation as described previously (Akaike and Moorhouse, 2003; Ye et al., 2004; Zhou et al., 2006 Data analyses. Spontaneous inhibitory postsynaptic currents (sIPSCs) were analyzed with Clampfit 9.2 software (Molecular Devices Corporation, Sunnyvale, U.S.A.) as described previously (Zhou et al., 2006) . Briefly, the sIPSCs were screened automatically using a template with an amplitude threshold of 5 pA. These were visually accepted or rejected based upon rise and decay times. More than 95% of the sIPSCs, which were visually accepted, were screened using a suitable template. The amplitudes and inter-event intervals of sIPSCs in different conditions were also obtained. Their cumulative probability distributions were constructed using 
Results
The identification of DA neurons. DA neurons in substantia nigra compacta (SNc) were identified on the basis of their well-established pharmacological and electrophysiological properties (Lacey et al., 1989; Zhou et al., 2006) . Mefloquine increases the frequency of miniature IPSCs (mIPSCs). To determine the location where mefloquine acts, we examined the effect of mefloquine on mIPSCs, in the presence of tetrodotoxin (TTX, 1 µ M) to eliminate action potential-induced spontaneous events.
As shown in figure 3A , 3 µ M mefloquine robustly increased mIPSC frequency. This is further illustrated in figure 3C , by the significant leftward shift of the cumulative probability plot of the intervals between successive mIPSCs, as well as by the accompanying histogram (K -S test, p < 0.01). In 5 neurons tested, 3 µM mefloquine increased the frequency of mIPSCs by 130 ± 10% (p < 0.001). In contrast, 3 µM mefloquine did not change the mean amplitude of the mIPSCs (Fig.   3C , right, K -S test, p = 0.8). The mean amplitude of mIPSCs in the presence of mefloquine was 101 ± 5% of control (p >0.05, n = 5). (Fig. 4A, D) , mefloquine induced potentiation of GABA release was not dependent on
Role of Ca
VGCCs.
This article has not been copyedited and formatted. The final version may differ from this version. To determine whether Ca 2+ influx was required in the action of mefloquine on sIPSCs, we compared the effect of mefloquine (3 µM) in normal medium and in medium containing lower Ca 2+ concentration. Mefloquine (3 µM) enhanced sIPSC frequency by 113 ± 20% in normal medium containing 2 mM Ca 2+ , but only by 36 ± 9% in medium containing 0.5 mM Ca 2+ (p < 0.05, n = 5) (Fig. 4B, D) . This indicates that mefloquine induced potentiation of GABA release was dependent on extracellular Ca 2+ .
To test whether intraterminal Ca 2+ contributes to the facilitation of mefloquine on sIPSC frequency, we examined the effect of BAPTA-AM, a membrane permeable Ca 2+ chelator. About 60-80 min after pretreatment with 30 µ M BAPTA-AM, 3 µ M mefloquine increased sIPSC frequency by 21 ± 11% (p = 0.3, n = 6) ( Fig. 4C, D) . Thus, mefloquine failed to increase sIPSC frequency after pretreatment with BAPTA-AM. These observations suggest that mefloquine induced potentiation of IPSC frequency requires an increase in Ca 2+ concentration within the presynaptic terminals.
Physostigmine attenuates mefloquine-induced potentiation of sIPSC frequency. It has been reported that mefloquine inhibits cholinesterase (Lim and Go, 1985; McArdle et al., 2005) .
Therefore, we next explored whether inhibition of cholinesterases with physostigmine can attenuate mefloquine-induced potentiation of sIPSC frequency. As shown in figure 5, 30 µ M physostigmine (PHY) alone increased sIPSC frequency by 50 ± 15% of control (p < 0.05, n = 5).
After the response to physostigmine had stabilized, the application of mefloquine continued to significantly enhance sIPSC frequency, by 31 ± 12% (p < 0.05, n = 5). However, this increase is much smaller than the enhancement induced by mefloquine alone (90 ± 10%) (p < 0.05, n = 5).
This suggests that mefloquine-induced enhancement of sIPSC frequency partially depends upon its anticholinesterase action. Additional mechanisms, including mobilization of intracellular Ca 2+ , are likely to mediate the remainder of the increase of sIPSC frequency (McArdle et al., 2006) .
Presynaptic nicotinic acetylcholine receptors (nAChRs) are involved in mefloquineinduced potentiation of sIPSC frequency. It is known that when acetyl-cholinesterase (AChE)
This article has not been copyedited and formatted. The final version may differ from this version. in the presynaptic sites of midbrain DA neurons (Mansvelder and McGehee, 2000; Wonnacott, 1997; MacDermott et al., 1999) . To further test whether mefloquine enhanced GABA release by its anticholinesterase action, we examined the contribution of α 7 and non-α 7 nAChRs to mefloquine-induced facilitation of sIPSC frequency.
After more than 10 minutes of pretreatment with α -Bungarotoxin (Bgtx) (300 nM), a specific α 7 nAChR antagonist, sIPSC frequency was not significantly altered (95 ± 6% of control, p = 0.21, n = 7, data not shown). 3 µ M mefloquine enhanced sIPSC frequency by 113 ± 12% (n = 7, p < 0.01) in the absence of α -Bungarotoxin, and by 118 ± 4% (p < 0.01, n = 6) in the presence of 300 nM α -Bungarotoxin (Fig. 6A, D ). Since these two values are equivalent (p > 0.5, n = 6), mefloquine induced potentiation of GABA release was independent of α 7 nAChRs.
After 5 min pre-incubation with mecamylamine (MEC) (10 µ M), a non-α7 nAChRs antagonist, sIPSC frequency was depressed by 20 ± 4% (p < 0.01, n = 6). Subsequent application of mefloquine increased sIPSC frequency by only 30 ± 9% (p < 0.01, n = 6), which was significantly less than that in the absence of MEC (Fig. 6B, D) . Similarly, the application of dihydro-β-erythroidine hydrobromide (DHβE) (100 nM), an antagonist for nAChRs containing α 4β2 subunits, depressed sIPSC frequency by 30 ± 4% (p < 0.01, n = 6). In the absence of DHβE, mefloquine (3 µ M) enhanced sIPSC frequency by 113 ± 12% (p < 0.01, n = 6). After a 5 min preincubation in DHβE (100 nM), mefloquine (3 µ M) -induced enhancement was significantly smaller, only by 28 ± 8% (p < 0.05, n = 6) ( Fig. 6C, D) . These results indicate that presynaptic nAChRs containing α 4β2  subunits are involved in mefloquine-induced potentiation of sIPSC frequency.
This article has not been copyedited and formatted. The final version may differ from this version. (Simpson et al., 1999; Kollaritsch et al., 2000) . Furthermore, mefloquine raises the frequency of spontaneous mIPSCs in the presence of tetrodotoxin, without altering their mean amplitude. These data suggest that mefloquine acts at the presynaptic site to increases GABA release.
The role of Ca 2+ in mefloquine enhanced GABA release. Ca 2+ influx into the terminals through voltage-gated calcium channels (VGCCs) is a common mechanism of modulation of transmitter release. Mefloquine blocks L-type VGCCs as well as volume-and calcium-activated chloride channels in crude microsomes prepared from brain (Lee and Go, 1996) . However, mefloquine-induced enhancement of sIPSC frequency did not change in the presence of Cd 2+ under our experimental conditions. This indicates that VGCCs are not involved in mefloquineinduced enhancement of sIPSCs. Interestingly, a decrease in extracellular Ca 2+ attenuated mefloquine-induced facilitation of GABA release. This indicates that the action of mefloquine depends on extracellular Ca 2+ . The residual Ca 2+ in nerve terminals is known to influence transmitter release (Creager et al., 1980; Augustine et al., 1987; Debanne et al., 1996; Mennerick and Zorumski, 1995; Sullivan, 1999) . In the presence of the high affinity membrane permeable Ca 2+ chelator BAPTA-AM, which can efficiently buffer intraterminal Ca 2+ , mefloquine-induced enhancement of GABA release was almost eliminated. This is consistent with previous findings at the neuromuscular junction (McArdle et al., 2006) . Taken together, mefloquine enhances GABA release by increasing Ca 2+ entry into GABAergic terminals, via pathways independent of This article has not been copyedited and formatted. The final version may differ from this version. Lee and Go, 1996) may also be involved in the action of mefloquine.
Anticholinesterase activity and presynaptic nAChRs mediate mefloquine-induced enhancement of GABA release. The SNc DA neurons receive cholinergic input from the pedunculopontine nucleus (Lichtensteiger et al., 1982; Clarke et al., 1985; Swanson et al., 1987; Bolam et al., 1991) . Both AChE and nAChRs are expressed in SNc (Henderson and Greenfield, 1984; Emmett and Greenfield, 2005) . ACh, released from cholinergic terminals activates nAChRs, induces influx of cations and excitation of dopaminergic neurons in SNc. AChE hydrolyses ACh, and terminates the action of ACh.
Both non-α7 and α 7-nAChRs are expressed in midbrain. However, in SNc, α 4β2-nAChRs express at high density. In contrast, α 7-nAChRs are at low density (Wooltorton et al., 2003) .
Nicotinic AChRs present on presynaptic terminals facilitate the release of many neurotransmitters, such as GABA, glutamate, serotonin and dopamine (McGehee et al., 1995; Wonnacott, 1997; MacDermott et al., 1999) . In the present study in SNc DA neurons, MEC, a non-α7 nAChRs antagonist, and DHβE, a selective antagonist of α 4β2 nAChRs, but not α -Bungarotoxin, a selective antagonist of α 7-nAChRs, depressed basal sIPSC frequency. These findings suggest the non-α7 nAChRs on GABAergic terminals are tonically activated. Because of its anticholinesterase action (Lim and Go, 1985; McArdle et al., 2005) , mefloquine may enhance GABA release via the activation of presynaptic nAChRs. In support of this hypothesis, mefloquine-induced enhancement of GABA release was attenuated in the presence of physostigmine. Thus, it is conceivable that mefloquine inhibits AChE which allows accumulation of ACh. The resultant activation of nAChRs on GABAergic terminals facilitates GABA release.
We attempted to identify the possible combinations of nAChR subunits on GABAergic terminals on rat SNc DA neurons. MEC and DHβE , but not α -Bungarotoxin, reduced mefloquine-induced GABAergic sIPSCs were recorded before, during and after application of 3 µM mefloquine in the presence of α -Bugarotoxin (BgTX, 300 nM) (A 1 ), mecamylamine hydrochloride (MEC, 10 µM) (B 1 ), and dihydro-β-erythroidine hydrobromide (DHβE, 100 nM) (C 1 ). Cumulative probability plots for inter-event interval are shown in A 2 (p < 0.05, K -S test), B 2 (p < 0.05, K -S test) and C 2 (p < 0.001, K -S test). D, Summary of the effect of 3 µM mefloquine on sIPSC frequency in the absence (MFQ) and presence of α -BgTX, MEC and DHβE (n = 6-7).
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